Advertisement

Topics

Sanofi expands R&D in China with €66m Chengdu Hub

11:55 EDT 3 Jul 2018 | BioPharma-Reporter

Sanofi will support development of polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies through the expansion of its R&D plant in Chengdu, Sichuan province, China.

Original Article: Sanofi expands R&D in China with €66m Chengdu Hub

NEXT ARTICLE

More From BioPortfolio on "Sanofi expands R&D in China with €66m Chengdu Hub"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...